Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Acquisitions & Divestments (2017 - 2022)

Arcus Biosciences (RCUS) has 6 years of Change in Acquisitions & Divestments data on record, last reported at $228.0 million in Q3 2022.

  • For Q3 2022, Change in Acquisitions & Divestments rose 70.93% year-over-year to $228.0 million; the TTM value through Sep 2022 reached $608.8 million, down 18.19%, while the annual FY2021 figure was $690.1 million, 124.53% up from the prior year.
  • Change in Acquisitions & Divestments reached $228.0 million in Q3 2022 per RCUS's latest filing, up from $169.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $251.4 million in Q1 2021 and bottomed at $25.6 million in Q1 2018.
  • Average Change in Acquisitions & Divestments over 5 years is $102.6 million, with a median of $87.3 million recorded in 2019.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 411.42% in 2021, then plummeted 62.68% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $42.3 million in 2018, then skyrocketed by 31.59% to $55.6 million in 2019, then surged by 209.42% to $172.0 million in 2020, then crashed by 31.45% to $117.9 million in 2021, then surged by 93.36% to $228.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $228.0 million in Q3 2022, $169.0 million in Q2 2022, and $93.8 million in Q1 2022.